Our Unique Consortium

Sydney Catalyst is a multi-disciplinary, multi-institutional endeavour established with core funding from the Cancer Institute NSW and based at the University of Sydney.

Read more

Event
EDS: Debate

Education Dinner Series

EDS: Debate

Debate 'The next big thing in cancer needs a revolution not more evolution.' REGISTER HERE The Grandstand Room 2, 1 Blackburn Circuit, The University of Sydney Three course dinn...

Read more
Event
Opening Invitation of The ACRF Image X Institute

Symposia

Opening Invitation of The ACRF Image X Institute

You are invited to attend the official opening of the ACRF IMAGE X INSTITUTE The Institute will link technological innovation with cancer research and treatment, focusing on imaging and...

Read more
News
Nutrition for people with head and neck cancer – translational cancer research study

News Articles

Nutrition for people with head and neck cancer – translational cancer research study

Sydney Catalyst member Merran Findlay is leading a study entitled: 'Best-evidence to best practice: Implementing an innovative model of care for nutritional management of patients with head an...

Read more
Research
Helen McGuire: Development of a novel test to predict clinical response to checkpoint therapy in lung cancer and mesothelioma

T1 | Flagship 2 Pilot and Seed

Helen McGuire: Development of a novel test to predict clinical response to checkpoint therapy in lung cancer and mesothelioma

Immune checkpoint inhibitor therapy has provided new hope to cancer patients whose tumours have resisted conventional therapy. One of the most recent success stories has been effective treatment o...

Read more
ImmunotherapyNew therapies and diagnosticsLung cancerMesothelioma
News
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

News Articles

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

Published online 1 September 2017 in the Lancet,  were results of a first-in-man study of TargomiRs. The study showed that a dose of 5 × 10⁹ TargomiRs per week was well tolerated and ...

Read more
Research
David Thomas & Team: Molecular Screening and Therapeutics Program (MOST)

T1,T2 | Sydney Catalyst Supported

David Thomas & Team: Molecular Screening and Therapeutics Program (MOST)

The rapid advance in genomic technologies presents the unprecedented opportunity to molecularly phenotype cancers and link genetic information to therapeutic opportunities for individual patie...

Read more
Genetics/genomicsPersonalised medicineNew therapies and diagnostics
News
Sydney Catalyst November 2017 Newsletter

News Articles

Sydney Catalyst November 2017 Newsletter

This month we've got an issue full to the brim with exciting news and events in the lead-up to Christmas. Two in particular will be hosted by Sydney Catalyst and we hope to see you there. This...

Read more
Research
Sydney Catalyst: Embedding Research in Cancer Healthcare (EnRICH)

T1,T2,T3 | Flagship 1 EnRICH

Sydney Catalyst: Embedding Research in Cancer Healthcare (EnRICH)

The program will develop infrastructure to support translational cancer research, initially with a focus on lung cancer. Specifically, EnRICH will assemble a prospective cohort of 1000 newly d...

Read more
Epidemiology and health services researchImplementation researchKnowledge translationLung cancer